Tumour responses 4 weeks after first TACE in patients randomised to the TACE plus sorafenib and TACE alone groups results reported as N (%)
| TACE plus sorafenib (n=80) | TACE alone (n=76) | P value* | |
| Best response | 0.77 | ||
| Complete response (CR) | 23 (28.8) | 21 (27.6) | |
| Partial response (PR) | 34 (42·.5) | 26 (34.2) | |
| Stable disease (SD) | 10 (12.5) | 12 (15.8) | |
| Progressive disease (PD) | 2 (2.5) | 3 (3.9) | |
| Not evaluable | 11 (13.8) | 14 (18.4) | |
| ORR (CR+PR) | 57 (71.3) | 47 (61.8) | 0.23 |
| DCR (CR+PR+SD) | 67 (83.8) | 59 (77.6) | 0.42 |
*By two-sided Fisher’s exact tests.
DCR, disease control rate; ORR, objective response rate; TACE, transarterial chemoembolisation.